Aikido

Aikido Security raises €5m to offer best-in-class noise reduction in its security solution for growing SaaS businesses

Retrieved on: 
Tuesday, November 14, 2023

The funds will be used to double down on its best-in-class user experience and auto-triaging, whilst expanding internationally.

Key Points: 
  • The funds will be used to double down on its best-in-class user experience and auto-triaging, whilst expanding internationally.
  • In today's digital landscape, where data breaches can cost companies an average of $4.45 million , Aikido Security is determined to revolutionize security solutions for growing SaaS businesses by offering an all-in-one platform that consolidates multiple aspects of application security into a single tool.
  • Willem Delbare, CEO & CTO of Aikido, highlights the security challenges faced by SaaS companies, explaining, "Startups often struggle with managing scattered security tools, resulting in noise and false positives that burden security staff.
  • By adopting a 'shift left' approach, Aikido prevents security issues from compromising code, allowing quick resolutions before production or breaches occur.

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

Retrieved on: 
Monday, November 28, 2022

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.

Key Points: 
  • Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI
    NEW YORK, Nov. 28, 2022 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI").
  • ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.
  • Mr. Anthony Hayes, CEO of AIkido stated, "As a shareholder of ASP Isotopes, we want to congratulate the company and their CEO, Paul Mann on successfully listing on NASDAQ.
  • We congratulate Paul and his team for getting this public offering over the line.

AIkido Share Repurchase Continues

Retrieved on: 
Thursday, October 6, 2022

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.
  • Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws.

AIkido Purchases More Shares

Retrieved on: 
Wednesday, October 5, 2022

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share.
  • Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

Share Repurchase Program Continues

Retrieved on: 
Tuesday, October 4, 2022

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 3, 2022, the Company purchased 45,000 shares of common stock at $6.98 per share.
  • The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

AIkido Pharma Continues Share Repurchase Program

Retrieved on: 
Monday, October 3, 2022

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share.
  • Anthony Hayes, CEO of Aikido stated, "The Company's stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

Seiryoku Zenyo, Jita Kyoei spirit is fundamental to Value Creation

Retrieved on: 
Friday, September 23, 2022

Sugai will speak in the final panel of the "Valuing Value: How any organization can measure stakeholder value" session.

Key Points: 
  • Sugai will speak in the final panel of the "Valuing Value: How any organization can measure stakeholder value" session.
  • "Yoshie Sugai-sensei's introduction of the philosophy of 'Seiryoku Zenyo, Jita Kyoei' from Jigoro Kano, the founder of Judo, and his student and founder of Yoseikan Budo, Minoru Mochizuki, is critically important to anyone who is serious about value creation in business or government.
  • Without the moral and ethical foundation that Yoshie will introduce, value creation efforts are bound to fail."
  • Free registration for the UNGA77 Science Summit, and further information on the Valuing Value workshop are available at https://sched.co/1AWkD.

Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer

Retrieved on: 
Friday, September 9, 2022

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm. This is Dominari's first acquisition since launching in June. Details of the proposed purchase can be found in the 8K on file with the SEC.

Key Points: 
  • Dominari Financial was formed with the intention of acquiring revenue generating assets in the fintech and financial services industry.
  • This transformative purchase not only accelerates our timetable, but also gives us the organizational infrastructure and technology needed to scale Dominari into a financial services powerhouse," said Carlos Aldavero, President of Dominari.
  • "The board fully supports the diversification strategy of which Dominari Financial is the centerpiece," added Wool.
  • "Once approved by FINRA, this acquisition will catapult Dominari forward and lays the groundwork for future acquisitions.

AIkido Pharma Confirms Receipt of Unsolicited Offer

Retrieved on: 
Wednesday, August 10, 2022

NEW YORK, Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.

Key Points: 
  • NEW YORK, Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Auerbach to acquire all of the Company's outstanding common stock for $8.00 per share in cash.
  • The Company's Board of Directors will carefully review the proposal to determine the course of action that it believes is in the best interest of the Company and all AIkido shareholders.
  • There is no need for shareholders to take any action at this time.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary

Retrieved on: 
Thursday, July 21, 2022

NEW YORK, July 21, 2022 /PRNewswire/ -- Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido. Mr. Aldavero joins Dominari from Morgan Stanley where he was Associate Complex Manager overseeing one of the largest and most profitable business units at the venerable Wall St. firm.

Key Points: 
  • Morgan Stanley Executive Joins Dominari Financial, Inc. on July 22, 2022
    NEW YORK, July 21, 2022 /PRNewswire/ --Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), announced the hiring of Carlos Aldavero as President of Dominari Financial, the recently formed financial services subsidiary of AIkido.
  • "We are thrilled to have someone with Carlos' extensive financial services experience and deep skill set take this key role in our organization," said Hayes.
  • Carlos will also work closely with me to identify additional key hires and build a world-class management team for the financial services division."
  • Dominari Financial, Inc. was formed by AIkido to make strategic investments and acquisitions of revenue generating assets in wealth management, investment banking, alternative investments, and asset management.